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Abstract
Background: Sarcomas are rare malignant tumors. Accurate initial histological diagnosis is essential for adequate 
management. We prospectively assessed the medical management of all patients diagnosed with sarcoma in a 
European region over a one-year period to identify the quantity of first diagnosis compared to central expert review 
(CER).
Methods: Histological data of all patients diagnosed with sarcoma in Rhone-Alpes between March 2005 and Feb 2006 
were collected. Primary diagnoses were systematically compared with second opinion from regional and national 
experts.
Results: Of 448 patients included, 366 (82%) matched the inclusion criteria and were analyzed. Of these, 199 (54%) had 
full concordance between primary diagnosis and second opinion (the first pathologist and the expert reached 
identical conclusions), 97 (27%) had partial concordance (identical diagnosis of conjonctive tumor but different grade 
or subtype), and 70 (19%) had complete discordance (different histological type or invalidation of the diagnosis of 
sarcoma). The major discrepancies were related to histological grade (n = 68, 19%), histological type (n = 39, 11%), 
subtype (n = 17, 5%), and grade plus subtype or grade plus histological type (n = 43, 12%).
Conclusions: Over 45% of first histological diagnoses were modified at second reading, possibly resulting in different 
treatment decisions. Systematic second expert opinion improves the quality of diagnosis and possibly the 
management of patients.
Background
Sarcomas are malignant tumors developing in soft tissue,
bone, skin or internal organs. The large majority of soft
tissue tumors are benign and 100 times more common
than malignant lesions [1,2]. Because there are more than
50 histological subtypes of soft tissue sarcoma (STS)
identified in the 2002 WHO classification, accurate diag-
nosis is difficult [3]. Given the rarity of the disease, inap-
propriate medical management has been reported in
more than 70% of patients with sarcomas [4]. Careful pre-
treatment evaluation is therefore essential for accurate
diagnosis and appropriate treatment decision making
[5,6]. Discrepancies between pathologists have been
reported frequently [7-10]. Although immunohistochem-
istry, Fluorescence In Situ Hybridization (FISH) and
molecular biology can facilitate diagnosis, these tech-
niques are not routinely available in all laboratories and
their use requires experienced pathologists with expertise
in molecular biology.
Second opinion in diagnostic pathology has recently
received considerable attention as a result of efforts to
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enhance institutional performance and reduce medical
errors [11]. However, the mechanisms by which second
opinion is obtained greatly influence the results [12]. Sec-
ond opinions given by another institution or a specialty
panel at the time of patient referral produce highly dis-
cordant rates as compared to analysis of cases referred to
experts for review [13]. In the case of expert review, dis-
crepancies are not viewed as "errors" but as a reflection of
the acknowledged need for assistance. For this we initi-
ated an exhaustive, prospective study involving the sys-
tematic comparison of initial histological diagnosis by a
first ('non-expert') pathologist and second opinion (SO)
from regional and/or national experts of the disease in a
comprehensive population of patients diagnosed in a pre-
cise geographical region over a one-year period.
Methods
Objectives
The main objective of the present work was to evaluate
the benefit of systematic central review by regional and
national experts of all sarcoma cases diagnosed in the
Rhône-Alpes region (RA). All sarcoma cases diagnosed
by pathologists of the region were reported, and data
were statistically analyzed to quantify inter-observer dif-
ferences and determine their nature.
Description of the Region
RA is the second largest region in France, with nearly 6
million inhabitants and 8 departements (i.e. the adminis-
trative and geographical unit in France). It has 15 public
structures (3 university hospitals, 1 cancer center, 11 gen-
eral hospitals) with 59 pathologists and 28 private struc-
tures with 80 pathologists.
Patient selection
To be eligible, patients had to meet the following inclu-
sion criteria: first diagnosis of connective tissue tumor,
according to the 2002 WHO definition, and no previous
treatment, first sarcoma diagnosis between March 1,
2005 and February 28, 2006 in RA region, all disease
stages, and age ≥ 15 years. Exclusion criteria were as fol-
lows: diagnosis of relapse or a diagnosis other than sar-
coma (i.e. low grade phyllodes tumor). Similarly, patients
were not included when primary diagnosis had been
established in the reference center (Leon Berard Cancer
Center) by one of the 'experts' or if the tumor specimen
was not sent to the expert or when there was not enough
tumor material. In order to include patients and assess
the concordance our study obtained an ethical approval
by a review board (CNIL: Commission Nationale de
l'information et des libertés. Independent administrative
authority protecting privacy and personal data). The
evaluation of medical records has been made through
clinical audit
Study design
The goal of this study was to compare initial histological
evaluation by the diagnostic pathologist (generally not an
expert on these diseases) and results of the central expert
review (CER) by two regional and national exclusively
soft tissue experts. These two experts, members of the
French Sarcoma Group (FSG), were selected by the EMS
project scientific committee. All pathologists working in
the region agreed to cooperate. All suspected cases of sar-
coma (soft tissue, bone and visceral tissue sarcoma; n =
671) diagnosed during the reference period were col-
lected [14].
For each patient, a copy of the original histology report
and histopathological specimens (Hemalin Eosin Safran
(HES) and paraffin-embedded tissue) representative of
the tumor sample were provided.
The diagnostic pathologist was offered financial com-
pensation for each patient included (50 euros). For all
included patients, immunohistochemistry (and/or
molecular biology analysis) was performed by the refer-
ent pathologist.
Exhaustiveness control
To ensure exhaustiveness, several controls were estab-
lished throughout the study by comparing the registered
patients with the complete list of: 1) sarcomas reviewed
by the expert pathologist every two months during the
inclusion period; 2) medical files of the multidisciplinary
sarcoma committee and patients obtained from the Med-
ical Information Department of the reference center; 3)
pediatric patients with sarcoma to confirm the number of
patients aged 15-18 and obtained from the pediatric reg-
istry of the RA region; 4) all sarcomas diagnosed by initial
pathologists; then we excluded patients with exclusion
criteria. After cross validation, only 5 additional patients
were identified as missing and included [15,16].
Main outcome measure
Differences between the first diagnosis established by the
non-expert pathologist and the second opinion given by
experts were evaluated and scored on a three-point scale:
The two experts evaluated in same time the diagnosis.
Zero agreement corresponded to cases where initial
diagnosis was benign and final diagnosis was malignant
(sarcoma) or conversely, or where the tumor was classi-
fied in different histological subtypes (i.e. synovialosar-
coma vs. liposarcoma).
Partial agreement corresponded to cases where both
pathologists diagnosed a sarcoma but with different his-
topathological grades, or with a different subtype (i.e.
dedifferentiated liposarcoma vs. myxoid round cell lipos-
arcoma).
Full agreement corresponded to cases where both
observers gave identical diagnoses.Lurkin et al. BMC Cancer 2010, 10:150
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To define this score, the two experts must conclude to
the same diagnose. In some rare cases and when the two
experts did not have the same conclusion or if the diag-
nose was difficult the diagnosis was reexamined either by
another expert (international expert Pr Fletcher) or/and
discussed at monthly FSG pathologist meetings and a
final consensus was determinated.
For all sarcoma types with mutation, a molecular biol-
ogy was systematically assessed (FISH technic, PCR or
DNA sequencing) to characterize the genetic alteration
and confirm the diagnose. The Immunomarques were
systematically done again by the expert
Grading system
The grading system of the French Sarcoma Group of the
French Federation of Cancer Centers (FNCLCC) was
used in this study as now proposed in the WHO classifi-
cation [17]. Grade was rated 'not applicable' for some spe-
cific histological types (e.g. Kaposi sarcoma) or when the
grade could not be determined (biopsy specimen).
Subgroup analysis
For all included cases, the pathologist investigators were
systematically offered an expert second opinion and the
discrepancies were analyzed. However, two groups of
patients were distinguished. The first one ("requested
SO" group) corresponded to patients examined by a "non
expert" pathologist who requested a second opinion from
experts to confirm initial diagnosis. The second group
("control" group) included patients whose tumor samples
were analyzed by a 'non expert' pathologist who did not
request confirmation of diagnosis by experts and whose
findings were reviewed only in the context of the present
project but the results were not disclosed.
Statistical analysis
To evaluate patient characteristics and diagnostic concor-
dance, categorical data were analyzed using Pearson's χ2-
test or Fisher's exact test, as appropriate. Continuous data
were analyzed with Student's t-test. The statistical signifi-
cance level was set at p = 0.05 in a two-sided test.
Comparisons were also made between the "requested
SO" group and controls. The χ2 test was used to deter-
mine the rate of concordance and the types of discor-
dance. Correlations between the most frequent causes of
error and groups were analyzed using the Kappa test. For
grading evaluation, a two by two table was constructed to
compare original diagnosis against final diagnosis, both
subsets being partitioned according to whether or not the
diagnosis was the type of sarcoma under consideration. A
Kappa test was used to measure agreement between ini-
tial diagnosis and expert review as compared to what
would be expected by chance alone [18,19]. All analyses
were performed using SPSS® (version 12.0) and SAS® soft-
wares.
Results
All values reported hereafter for grade, histology and type
or site of sarcoma are those obtained after expert review.
Characteristics of selected patients and tumors
Of 671 patients initially screened by pathology laborato-
ries, 220 (33%) were excluded, either because of patient
age < 15 (n = 26, 4%), local relapse (n = 92, 14%), meta-
static relapse (n = 40, 6%), or because the patient had not
been firstly diagnosed in RA (n = 36, 5%) or had not been
diagnosed between March 2005 and Feb 2006 (n = 26,
4%). Among the 451 selected patients, 52 (12%) were fur-
ther excluded because initial diagnosis had been estab-
lished in the reference center by one of the experts. Of the
399 remaining patients, 29 (7%) were excluded because
there was no or not enough tumor tissue available for a
second histological analysis and 4 (1%) because the initial
histological report was not available. Finally, 366 (92%)
patients were eligible for final analysis (Figure 1). The first
diagnosis of sarcoma was performed in private practice
for 265 (72%) patients and in public laboratories for 101
(28%) patients. Only 2 laboratories did not recruit any
patient.
Characteristics of included patients and tumors
Patients' characteristics are reported in Table 1. Among
the 366 analyzed patients, 184 were males (50%) and 182
were females (50%). Median age was 61 years (range, 15-
92): 60 (range, 15-92) for males and 63 (range, 16-91) for
females.
Concordance analysis
Concordance analysis was performed on 93 (25%) sar-
coma biopsy specimens and 273 (75%) surgical samples.
Concordance data regarding grade, type of tumor sample
(biopsy vs. surgery) and type of laboratory (private vs.
Figure 1 Patient selection.
52 patients initially diagnosed in the 
reference cancer center   
Concordance 
assessment
399 included patients
451 selected patients
178  patients (49%) 
366 patients available (82%)
33 tumor samples not 
available for histological 
review 
188 patients (51%) 
 92 % of samples
Second opinion requested  Second opinion not requested Lurkin et al. BMC Cancer 2010, 10:150
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Table 1: Characteristics of included patients
Number %
Included patients 366 100%
Types of sarcoma
Soft tissue 215 59
Visceral tissue 130 35
Bone tissue 21 6
Tumor site
Abdomen 101 27.6
Lower limb 76 20.8
Thorax 54 14.8
Pelvis 45 12.3
Upper limb 34 9.3
Head and Neck 29 7.9
Retroperitoneum 21 5.7
Multiple localizations 5 1.4
Axial skeleton 1 0.3
Histological subtype
GIST 65 17.8
Liposarcoma 56 15.3
NOS Sarcoma * 52 14.2
Other ** 38 10.3
Leiomyosarcoma 26 7.1
Dermatofibrosarcoma protuberans 20 5.5
Kaposi sarcoma 18 4.9
Uterine leiomyosarcoma 12 3.3
Myxofibrosarcoma 12 3.3
Osteosarcoma 11 3.0
Angiosarcoma 10 2.7
Chondrosarcoma 9 2.5
PNET/Ewing sarcoma 8 2,2
Rhabdomyosarcoma 8 2.2
Synovial sarcoma 7 1,9
Unclassified malignant connective 
tumors
14 3.8
Grade
I8 5 2 3 . 2
II 77 21.0
III 97 26.5
Not applicable*** 103 28.1
Unknown 4 1.1
* NOS = not otherwise specified.
**The 'other' category included sarcoma subtypes with less than 5 patients and tumors initially described as sarcomas and reclassified by the 
experts as carcinomas or sarcomatoid carcinomas
**Not applicable (Kaposi sarcoma, for instance)Lurkin et al. BMC Cancer 2010, 10:150
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public) are given in Table 2. Concordance analysis
showed 70 cases of zero agreement (19%), 97 partial
agreements (27%) and 199 full agreements (54%). The
r a t e  o f  d i s c o r d a n c e  w a s  h i g h e r  i n  g r a d e  I I - I I I  t h a n  i n
grade I tumors (p = 0.012). On the other hand, no signifi-
cant differences were reported according to type of tumor
sample, type of laboratory and molecular biology exami-
nation (yes vs. no) (Table 2). The molecular biology tech-
niques used were the Fluorescence in situ hybridization
(FISH), the PCR and DNA sequencing.
Causes of non-concordance are presented in Table 3.
Discrepancies between initial diagnosis and review were
essentially related to grade and histological subtype.
Details of zero and partial agreements are given in Table 4
and Additional File 1, respectively. More precisely, in the
zero concordance group, the diagnoses were changed
from benign to malignant for 7 patients. The modifica-
tion of diagnosis between malignant tumor and benign
have been concerning 3 patients. The most frequent dis-
crepancy was related to the grade of the tumor: either no
grading by the diagnostic pathologist while the expert
attributed grade 3 (n = 33, 20%), or misinterpretation of
the grading with grade 3 attributed by the diagnostic
pathologist and grade 1 by the expert (n = 3, 2%). Other
(n = 131, 78%) discrepancies were related to the grade (0
vs. I, I vs. II, II vs. III) and histological subtype. We mea-
sured the chance-corrected agreement on grade between
groups using the Kappa test. The Kappa coefficient was
0.7857 (p < 0.0001), which reflected a high level of agree-
ment. The major cause of discrepancies was the very high
proportion (n = 85, 66%) of tumors not graded by diag-
nostic pathologists. However, when diagnostic patholo-
gists did grade the tumors, their grading was generally
correct (Additional File 1).
The second most frequent discrepancy was related to
the histological type (Table 4). In 22 (31%) patients the
diagnosis reviewed and modified by the expert concerned
benign tumor or sarcomatoid carcinoma.
Table 2: Concordance analysis
Concordance Zero Partial Full p
Included tumors 70 (100%) 97 (100%) 199 (100%)
Type of laboratory
Public 17 (16.8%) 28 (27.7%) 56 (55.4%) 0.78
Private 53 (20%) 69 (26.%) 143 (54%)
Concordance Zero Partial Full p
Included tumors 70 97 97
Type of tumor sample
Biopsy 16 (17.2%) 23 (24.7%) 54 (58.1%) 0.70
Surgical 
specimen
54 (19.8%) 74 (27.1%) 145 (53.1%)
Concordance Zero Partial Full p
Included tumors 44 81 134
Grade
I 9 (10.6%) 21 (24.7%) 55 (64.7%) 0.01
II-III 35 (20.1%) 60 (34.5%) 79 (45.4%)
Concordance Zero Partial Full p
Included tumors 67 97 199
Molecular biology 
study
No 45 (20%) 61 (26.%) 127 (54%) 0.84
Yes 23(17.6%) 36 (27.5%) 72 (55.0%)Lurkin et al. BMC Cancer 2010, 10:150
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Diagnosis was confirmed by molecular biology (RT-
PCR, FISH) in 131 (36%) patients: 72 (55%) in the
"requested SO" group and 59 (45%) in the control group
at the request of the expert reviewer. Seventy-two (55%)
tests were performed in the group with full concordance,
36 (27%) with partial concordance and 23 (18%) with zero
concordance. Eighty-seven (66%) of these 131 molecular
biology tests were positive, 32 (24%) were negative and 12
(9%) were non significant. They were performed essen-
tially in patients with GIST (n = 41, 31%), liposarcoma (n
= 39; 30%) and dermatofibrosarcoma protuberans (n =
11, 8%). Final diagnosis could not be established by the
first expert for 20 (5%) patients, and the case was submit-
ted to other sarcoma experts for second opinion (French
sarcoma group).
Requested SO group versus control group
For the two groups of patients distinguished, the charac-
teristics are compared in Tables 5 and Additional File 2.
Only three items seemed different between subgroups:
type of samples, type of laboratory and histological sub-
type. The patients for whom initial diagnosis had been
made from biopsy specimens were most frequently not
proposed for a SO. Likewise, the majority of patients
included in the group without SO were first diagnosed in
public laboratories. For all other factors no differences
were noted. In fact, non expert pathologists asked for a
second expert opinion principally for difficult diagnoses
or cases requiring molecular analysis (n = 188). Sex, age,
type of tumor, or tumor localization and grade did not
influence the decision of the first pathologist to request a
second opinion (Table 5).
Concordance results in the two subgroups of patients
The concordance observed between the two groups of
patients is described in Table 6. Not surprisingly, concor-
dance was significantly better in cases where the primary
pathologist did not ask for a second opinion as compared
to cases where an expert second opinion was requested
spontaneously (66% vs. 44%) (p < 0.001). Reasons for
non-concordance were tested in both groups. The type of
sample and the type of laboratory were not found corre-
lated to concordance, with respectively 40 (70%) vs. 77
(63%) (p = 0.62), and 82 (68%) vs. 35 (60%) (p = 0.39) full
concordance in the group without SO. In the group with
SO, full concordance results were 14 (39%) vs. 68 (44%) (p
= 0.72) and 61 (42%) vs. 21 (48%) (p = 0.66).
Discussion
F u l l  c o n c o r d a n c e  w a s  r e p o r t e d  f o r  o n l y  5 4 %  o f  c a s e s
included in this comprehensive cohort of sarcoma
patients treated in RA in one year. Indeed, accurate diag-
nosis is essential to ensure appropriate management of
patients with sarcoma, especially in the context of new
targeted therapies. This study confirmed that centralized
pathological review improves the quality of diagnosis in
these rare tumors.
This study confirms that the diagnosis of sarcoma is
ve ry di fficul t  t o  esta blis h s inc e  mo r e  t ha n 45% of  fir st
diagnoses were declared invalid by the panel of experts
conducting the centralized pathological review. The
major result was that concordance seems independent of
the type of laboratory providing the primary diagnosis,
the nature of the tumor samples or the tissue affected by
the sarcoma (bone, soft tissue, viscera). The most fre-
quent discrepancies identified were related to tumor
grade and histological type. Exact determination of the
tumor type and grade is crucial for making individual
treatment decisions and subsequently improving patient
outcome [20,21]. In fact, determining the grade of the
tumor is essential to decide between adjuvant chemo-
therapy or not, neo-adjuvant chemotherapy or not, or
radiotherapy or not. With the introduction of targeted
treatments and the proliferation of clinical studies,
patients whose grade has not been correctly evaluated
may be excluded from trials [20-23]. Although the clinical
practice recommendations published in France have con-
firmed that the tumor grade must be included in the his-
Table 3: Reasons for non-concordance
Reasons for non-concordance Frequency %
Grade 68 18.5
Histological type 39 10.7
Grade and Histological type 30 8.2
Subtype 17 4.6
Grade and subtype 13 3.6
SUB-TOTAL 167 45.6
Patient with total agreement 199 54.4
TOTAL 366 100Lurkin et al. BMC Cancer 2010, 10:150
http://www.biomedcentral.com/1471-2407/10/150
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Table 4: Diagnostic differences in cases with zero concordance
Expert diagnosis Initial diagnosis Frequency
(n = 70)
NOS Sarcoma MPNST 1
NOS Sarcoma Angiosarcoma 1
NOS Sarcoma Unclassified malignant tumor 6
NOS Sarcoma Leiomyosarcoma 1
NOS Sarcoma GIST 1
NOS Sarcoma Chondrosarcoma 1
NOS Sarcoma Embryonic Rhabdomyosarcoma 1
NOS Sarcoma Benign Tumor 1
NOS Sarcoma Liposarcoma 1
NOS Sarcoma Leiomyosarcoma 2
Leiomyosarcoma Benign Tumor 2
Leiomyosarcoma NOS Sarcoma 1
Osteosarcoma NOS Sarcoma 1
Osteosarcoma Unclassified malignant tumor 1
Osteosarcoma Melanoma 1
Lipoma-like Liposarcoma Benign Tumor 1
Lipoma-like Liposarcoma Fibrosarcoma 1
Lipoma-like Liposarcoma Unclassified malignant tumor 1
Liposarcoma Benign Tumor 1
Liposarcoma NOS Sarcoma 2
Dedif. Liposarcoma Leiomyosarcoma 2
Dedif. Liposarcoma Unclassified malignant tumor 1
Dedif. Liposarcoma NOS Sarcoma 1
Myxofibrosarcoma Liposarcoma 1
Myxofibrosarcoma NOS Sarcoma 3
Myxofibrosarcoma Sarcomatoid Carcinoma 1
Myxofibrosarcoma Chondrosarcoma 1
Sarcomatoid Carcinoma Leiomyosarcoma 1
Sarcomatoid Carcinoma NOS Sarcoma 3
Angiosarcoma Unclassified malignant tumor 1
Angiosarcoma Synovial sarcoma 1
Benign Tumor Inflammatory MyxofibroSarcoma 1
Benign Tumor Leiomyosarcoma 1
Benign Tumor Well-differenciated lipoma-like 
Liposarcoma
1
Epithelioid Sarcoma Unclassified malignant tumor 1
Epithelioid Sarcoma Synovial sarcoma 1
PNET/Ewing sarcoma Carcinoma 2
PNET/Ewing sarcoma Unclassified malignant tumor 3
Rhabdomyosarcoma Leiomyosarcoma 1
GIST NOS Sarcoma 1
Carcinoma Phyllodes Tumor 1Lurkin et al. BMC Cancer 2010, 10:150
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tological report generated at the time of diagnosis, this
information is not always given, as confirmed in other
studies demonstrating that the reproducibility of grade is
very difficult to achieve [20,23-25]. On the other hand,
when non expert pathologists participating in the study
did grade a tumor, their evaluation was generally correct.
Pathologists may sometimes lack experience and would
benefit from training sessions organized in the frame-
work of continuous medical education [26].
Accurate determination of the type of sarcoma lesion is
also crucial for correct patient management especially for
differentiating between benign and malignant tumors, or
between the different subtypes [27]. Determining the
grade of the tumor is more reproducible than character-
izing its histological type which is the second cause of
diagnostic discordance [8]. The second cause of discrep-
ancies concerned the histological type, and the central
question that arises is whether all sarcoma cases should
be reviewed in a specialized center. Importantly, all
pathologists evaluating sarcoma patients should be able
to use immunohistochemistry for confirmation of diag-
nosis. For certain histological types (GIST, Dermatofibro-
sarcoma protuberans...), molecular biology can also
contribute to the establishment and/or the confirmation
of diagnosis [28-32]. Non concordance between first
diagnosis and review seems very frequent for liposar-
coma, PNET tumor and NOS sarcoma, and it is high for
GIST and dermatofibrosarcoma protuberans for which
specific markers are available. Similar results were
reported by Harris et al, with a high degree of agreement
for osteosarcoma and chondrosarcoma and low agree-
ment for leiomyosarcoma and malignant fibrous histiocy-
toma [27,28].
In the literature, the rate of diagnostic errors in patients
with soft tissue sarcoma is between 25% and 40%. [6-
10,33-37], Surprisingly, since the first published reports
on second opinion for sarcoma tumors in 1980, despite
the introduction of new tools (immunochemistry, molec-
ular biology etc.) and the development of educational
workshops, the percentage of concordance has remained
unchanged. Disagreements between diagnostic patholo-
gists and expert panel members are inescapable (unrepre-
sentative samples, heterogeneous tumors, misdiagnosis
of grading...). In spite of the relatively high incidence of
sarcoma, such variations in diagnosis will continue to
occur and no significant convergence can be expected
over time [14]. Our comprehensive prospective study
confirmed the results of previous retrospective studies,
with inconsistencies between primary diagnosis and his-
tological review in 45% of all cases. Our results revealed
that diagnostic pathologists were often lack expertise in
this disease or in other rare tumors. Thus, systematic
expert second opinion seems essential [35]. The inexperi-
ence of non-specialists with the multitude and complex-
ity of soft tissue sarcomas is probably the most important
factor accounting for diagnostic discrepancies [27]. Actu-
ally, this question of centralized diagnosis is less relevant
for tumors with more "standardized" diagnosis and man-
agement, like carcinoma or ovarian cancer [38,39].
In this study , 50% of the tumors were spontaneously
addressed for a second opinion by the non-expert pathol-
ogist, versus only 40% in a previous study[25]. All pathol-
Carcinoma NOS Sarcoma 1
Solitary fibrosis/malignant Tumor GIST 1
Uterine Leiomyosarcoma Benign Tumor 1
PEComa Unclassified malignant tumor 1
Fibrosarcoma Unclassified malignant tumor 1
Endometrial Stromal Sarcoma Leiomyosarcoma 1
Epithelioid Hemangioendothelioma Carcinoma 1
Inflammatory Myxofibrosarcoma Epithelioid Sarcoma 1
Unclassified malignant tumor Carcinoma 1
Low grade fibromyxoid Sarcoma Benign Tumor 1
Kaposi sarcoma NOS Sarcoma 1
Synovial sarcoma Benign Tumor 1
Dermatofibrosarcoma protuberans Benign Tumor 1
NOS: not otherwise specified
PNET: primitive neuroectodermal tumor
GIST: gastrointestinal stromal tumor
PEComa: malignant perivascular epithelioid cell tumor
MPNST: malignant peripheral nerve sheath tumor
Table 4: Diagnostic differences in cases with zero concordance (Continued)Lurkin et al. BMC Cancer 2010, 10:150
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Table 5: Patient characteristics per subgroup
Patient characteristics.
requested SO group Control group p
Included patients 188 (100%) 178 (100%)
Sex
Males 102 (54.3%) 82 (46.1%) 0.117
Females 86 (45.7%) 96 (53.9%)
Age (years)
Mean 57.9 59.6
Median 62 61 0.359
Range [15-86] [18-92]
Types of tumor
Soft tissue 117 (62.2%) 98 (55.1%)
Bone tissue 13 (6.9%) 8 (4.5%) 0.128
Visceral tissue 58 (30.9%) 72 (40.4%)
Localization
Upper limb 15 (8.%) 19 (10.7%)
Lower limb 45 (23.9%) 31 (17.4%)
Abdomen 44 (23.4%) 57 (32%)
Thorax 31 (16.5%) 23 (12.9%) 0.313
Head and Neck 16 (8.5%) 13 (7.3%)
Pelvis 25 (13.3%) 20 (11.2%)
Retroperitoneum 10 (5.3%) 11 (6.2%)
Axial skeleton 1 (0.5%) 0 (0%)
Multiple localizations 1 (0.5%) 4 (2.2%)
Grade
Grade I 47 (25%) 38 (21.3%)
Grade II 36 (19.1%) 41 (23%)
Grade III 50 (26.6%) 47 (26.4%) 0.716
Non applicable 52 (27.2%) 51 (28.7%)
Unknown 3 (1.6%) 1 (0.6%)
Histological subtypes
Liposarcoma 37 (19.7%) 19 (10.7%)
NOS Sarcoma 32 (17.0%) 20 (11.2%)
GIST 23 (12.2%) 42 (23.6%)
Myxofibrosarcoma 9 (4.8%) 3 (1.7%)
Leiomyosarcoma 7 (3.7%) 19 (10.7%)
PNET/Ewing 6 (3.2%) 2 (1.1%)
Rhabdomyosarcoma 6 (3.2%) 2 (1.1%)  < 0.001.Lurkin et al. BMC Cancer 2010, 10:150
http://www.biomedcentral.com/1471-2407/10/150
Page 10 of 12
ogists in the RA region took part in the study and full
comprehensiveness was achieved. However, to achieve
such a successful recruitment, many requirements must
be met. In particular, there must be a key opinion leader
and expert pathologist with recognized expertise in the
field. Financial support to the pathologists participating
in the study also seems essential. Finally, it is important,
to keep the pathologists informed through regular meet-
ings and newsletters. They must be involved and get feed-
back about the final diagnosis of their patient as well as
about the advancement of the study. Cancer network par-
ticipation can facilitate the involvement of pathologists
and ensure exhaustiveness. It is well established in sar-
coma pathology that "expert" opinion is not always abso-
lutely convergent, though often different
conceptualizations of a tumor do not necessarily generate
different treatment implications. With the help of CON-
TICANET (CONnective TIssue CAncer NETwork), a
similar prospective study has been initiated in the Aquit-
aine (France) and Venetia (Italy) regions to compare the
rate of diagnostic discordance and confirm our conclu-
sions. The correlation between concordance and free sur-
vival will be essentially evaluated on grade II/III tumors.
The assessment of concordance is important for the
patient for its impact on the diagnosis. The optimal diag-
nosis but also the optimum treatments (R0, radiotherapy
decision) have an important role. Their prognostic value
will be determinate in another article.
Conclusion
In conclusion, the inexperience of non-specialized
pathologists with the multitude and complexity of sar-
Chondrosarcoma 6 (3.2%) 3 (1.7%)
Dermatofibrosarcoma 4 (2.1%) 16 (9.0%)
protuberans
Uterine 
Leiomyosarcoma
5 (2.7%) 7 (3.9%)
Osteosarcoma 5 (2.7%) 6 (3.4%)
Kaposi Sarcoma 5 (2.7%) 13 (7.3%)
Synovialosarcoma 5 (2.7%) 2 (1.1%)
Angiosarcoma 3 (1.6%) 7 (3.9%)
Unclassified malignant 
tumor
7 (3.7%) 7 (3.9%)
Other 28 (14.9%) 10 (5.6%)
Table 5: Patient characteristics per subgroup (Continued)
Table 6: Comparison of concordance results in the two groups
Requested SO group Control group p
Included patients 188 (100%) 178 (100%)
Concordance
Zero 53 (28.2%) 17 (9.6%)
Partial 53 (28.2%) 44 (24.7%)  < 0.001.
Full 82 (43.6%) 117 (65.7%)
Included patients 106 (100%) 61 (100%)
Type of discordance
Subtype alone 10 (9.4%) 7 (11.5%)
Grade alone 31 (29.2%) 37 (60.7%)
Histological type alone 27 (25.5%) 12 (19.7%)  < 0.001
Grade + Subtype 13 (12.3%) 0 (0%)
Grade + Histological 
type
25 (23.6%) 5 (8.2%)Lurkin et al. BMC Cancer 2010, 10:150
http://www.biomedcentral.com/1471-2407/10/150
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coma tumors, and the non availability of new molecular
diagnostic tools are the most important factors account-
ing for diagnosis discrepancies. A centralized pathologi-
cal review, a rapid and efficient help with access to
molecular biology analysis seem of vital importance in
these rare tumors. More efficient information and educa-
tion of the pathologists also seems essential to ensure
accurate diagnosis and grading [31].
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